Search Results 151-160 of 17431 for Mmol

1. Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma - Mayo Clinic

   Hemoglobin < 8 g/dL (< 4.9 mmol/L) (transfusion is not permitted within 21 days of screening);; Creatinine clearance (CrCl) as reported below;; Corrected ...

2. EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx - Mayo Clinic

   Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x109/L (2000/mm3); platelets <75x109/L (75x103/mm3). Total bilirubin >3 x ULN. Serum albumin <3.0 g/dL ...

3. A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Corrected serum calcium. ≤ 12.5 mg/dL (≤3.1 mmol/L) or free ionized calcium ≤ 6.5 mg/dl (≤1.6 mmol/L). * For subjects who meet the inclusion criteria at ...

4. OHF Patient Registry - Mayo Clinic

   Urinary oxalate excretion of greater than 0.8 mmol/1.73 m2/day (>70 mg/1.73 m2/day) in the. absence of a gastrointestinal disease known to cause ...

5. Testing Teclistamab (TECVAYLI) In Combination With Iberdomide For Hard-to-Treat Multiple Myeloma - Mayo Clinic

   ... mmol) OR urine dipstick negative/trace (if \> 1+ only eligible if confirmed ≤ 500 mg/g (56 mg/mmol) by albumin/creatinine ratio (spot urine from first void) ...

6. AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II - Mayo Clinic

   Participation eligibility · Subject has severe anemia defined as hemoglobin < 8.0 g/dL (< 4.9 mmol/L). · Subject has impaired renal function as defined by an eGFR ...

7. A Study to Evaluate Sacubitril-Valsartan for Left Ventricular Reverse Remodeling in Adults with Congenital Heart Abnormality - Mayo Clinic

   Hyperkalemia defined as serum potassium > 5.2 mmol/l. Hypotension defined as systolic blood pressure < 100 mmHg. History of angioedema. Pregnancy ...

8. A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma - Mayo Clinic

   Subject has absolute neutrophil count < 1000/μL, platelet count < 75,000/μL, and hemoglobin < 8 g/dL (< 5 mmol/L) at Screening; Subject has total serum ...

9. A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma - Mayo Clinic

   Hypercalcemia (serum calcium >0.25 mmol/L [>1 mg/dL] higher than ULN or >2.75 mmol/L [>11 mg/dL]). Subjects who have clinically stable hypercalcemia ...

10. Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) - Mayo Clinic

    ... millimoles per liter [mmol/L]) at screening and 8-11.0 g/dL (5 to 6.8 mmol/L) at randomization. Capable of giving signed informed consent which includes ...